|
Overview
Our Mission
The mission of IBI is to apply BioFlash-Dx™ technology to develop next generation in vitro diagnostics that address the health care needs in the developed and the developing world to maximize the speed, affordability and accessibility of results where it matters most to improve the human condition.
Our History
These efforts are rooted in the work of the MIT Lincoln Laboratory (“Laboratory”). The Laboratory recognized that the growing threats posed by pathogens — whether in intentional bioagent attacks or through unintentional spread of disease — have intensified the demand for a pathogen detection and identification method that can rapidly provide pathogen identification before a population is infected.
The Laboratory developed biosensors that significantly improve the speed and sensitivity of bioagent identification. These biosensors use a Laboratory-developed technology called CANARY® (for Cellular Analysis and Notification of Antigen Risks and Yields).
CANARY uses one of nature’s bioidentifiers, B cells, the fastest pathogen identifiers known. B cells are a type of white blood cell that binds to and recognizes pathogens.
The Laboratory genetically engineered B cells to bind specifically to pathogens of interest and then, within seconds, to emit photons that indicate that binding and pathogen recognition have occurred. The photons are detected by a luminometer.
Prototype sensors were built by the Laboratory and validated and are now used in fielded bioagent detection applications.
The technology was licensed exclusively to IBI for further development and commercialization for the environmental and clinical diagnostic markets.